Noxafil
Noxafil contains posaconazole, a triazole antifungal agent. It prevents and treats a wide range of invasive fungal infections by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.
Dosage by Body Weight
Dosages of oral suspension and delayed-release tablets are not interchangeable. Tablets are typically taken with or without food, while the oral suspension must be taken with a full meal or nutritional supplement. Dosage must be adjusted in patients with severe renal impairment or hepatic impairment under medical supervision.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy in pediatric patients under 2 years of age or below this weight have not been established.
- Body Weight
- 5-7 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by physician
- Tracking Notes
- Systemic triazole antifungals require precise body surface area (BSA) calculation or therapeutic drug monitoring in young children.
- Body Weight
- 8-10 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by physician
- Tracking Notes
- For pediatric patients, dosing is highly specialized and often based on body surface area (BSA) rather than fixed weight bands.
- Body Weight
- 11-15 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by physician
- Tracking Notes
- Delayed-release oral suspension may be dosed based on weight/BSA in children aged 2 and older. Strict medical supervision required.
- Body Weight
- 16-20 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by physician
- Tracking Notes
- Dosing must be guided by a specialist and monitored using therapeutic drug monitoring (TDM) to ensure therapeutic serum concentrations.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Safety and efficacy in pediatric patients under 2 years of age or below this weight have not been established. |
| 5-7 kg | Requires specialist calculation | As directed by physician | Systemic triazole antifungals require precise body surface area (BSA) calculation or therapeutic drug monitoring in young children. |
| 8-10 kg | Requires specialist calculation | As directed by physician | For pediatric patients, dosing is highly specialized and often based on body surface area (BSA) rather than fixed weight bands. |
| 11-15 kg | Requires specialist calculation | As directed by physician | Delayed-release oral suspension may be dosed based on weight/BSA in children aged 2 and older. Strict medical supervision required. |
| 16-20 kg | Requires specialist calculation | As directed by physician | Dosing must be guided by a specialist and monitored using therapeutic drug monitoring (TDM) to ensure therapeutic serum concentrations. |
Formulation
Purpose
Prevention of invasive Aspergillus and Candida infections in severely immunocompromised patients, and treatment of oropharyngeal candidiasis (thrush).
Generic Name
PosaconazoleScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.